Monoclonal Antibody Therapeutics Market Is Booming Across the Globe Explored in Latest Report 2020-2025 | Analysis by Key Players - Pfizer, Sanofi, GlaxoSmithKline, Merck, Novartis, AbbVie

Global Monoclonal Antibody Therapeutics Market overview:

The growing demand for Monoclonal Antibody Therapeutics has provided a major boost to the Global Monoclonal Antibody Therapeutics Market as more people are shifting their preferences to this growing sector. The market is expected to keep rising at a high CAGR and reach values of high millions by the end of the forecast period of 2020 up to 2024.

Get Access to Report Sample @ https://www.businessindustryreports.com/sample-request/263490

The biological therapy used for treating various kinds of severe and chronic conditions are known as monoclonal antibodies. These are applied in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn’s diseases, psoriasis, osteoporosis, systemic lupus erythematous and others. These are target only the affected areas to destroy the diseased cells, thus restoring the immune system. The global Monoclonal Antibody Therapeutics Market is primarily segmented based on Product Type, Application, End-Use Industry and Regions.

Based on Product Type, the market is divided into:

1 Humanized Antibody

2 Human Mouse Chimeric Antibody

On the basis of End Use Industry, the market is split into:

1 Cancer

2 Autoimmune Diseases

3 Infection

4 Hematological Diseases

5 Ophthalmological Diseases

6 Others

The global monoclonal antibody therapeutics market is segmented into cancer, ophthalmological diseases, infection, autoimmune diseases, and hematological diseases among others. Of these, demand for treating autoimmune diseases with monoclonal antibody therapeutics is expected to remain at an all-time high in the coming years. The growing awareness about diseases, improving accessibility to healthcare, widening range of monoclonal antibody therapeutics, and huge investments in research and development of these therapeutics are expected to propel the segment in the coming years. Cancer is the second largest segment in the global market due to the high prevalence of the disease and an urgent need to treat the same.

Objectives of the Study

To describe and forecast the global Monoclonal Antibody Therapeutics Market on the basis of Product Type, industry verticals, Channel and regions.

To forecast the Monoclonal Antibody Therapeutics Market size of the five main regional segments, namely North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and Latin America.

To strategically analyzesubsegments with respect to individual growth trends, future prospects, and contribution to the total market.

To provide detailed information regarding the major factors influencing the growth of the Monoclonal Antibody Therapeutics Market (drivers, restraints, opportunities, and challenges).

To analyze the opportunities in the market for stakeholders and to provide details of competitive landscape for major players.

To strategically profile key players and comprehensively analyze their core competencies and positioning.

To track and analyze competitive developments such as mergers and acquisitions, new product developments, and partnerships, agreements & collaborations in the Monoclonal Antibody Therapeutics Market.

 

Some of the Monoclonal Antibody Therapeutics Market manufacturers involved in the market are Bayer, F. Hoffmann-La Roche, Pfizer, Sanofi, GlaxoSmithKline, Merck, Novartis, AbbVie, Amgen, Johnson & Johnson, Bristol-Myers Squibb Company, Biogen, Acquisitions and effective mergers are some of the strategies adopted by the Monoclonal Antibody Therapeutics Market manufacturers. New product launches and continuous technological innovations are the Monoclonal Antibody Therapeutics Market strategies adopted by the major players.

Latest Industry Updates:

Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for tanezumab 2.5 mg administered subcutaneously (SC), which is being evaluated for patients with chronic pain due to moderate-to-severe osteoarthritis (OA) who have experienced inadequate pain relief with other analgesics. Tanezumab is a monoclonal antibody that is part of an investigational class of non-opioid chronic pain medications known as nerve growth factor (NGF) inhibitors.

More than 27 million Americans are living with OA, 11 million of whom have moderate-to-severe OA. Currently available treatment options for moderate-to-severe OA do not meet the needs of all patients, and many cycle through multiple therapies to find relief from their pain. The Prescription Drug User Fee Act (PDUFA) goal date for the FDA to make a decision on the tanezumab application is in December 2020. In its acceptance letter, the FDA stated that it is currently planning to hold an Advisory Committee meeting to discuss this application.

"The FDA acceptance of the tanezumab application represents a significant milestone, and the breadth of our regulatory submission reflects the extensive clinical data we have gathered for tanezumab over the course of its development," said Ken Verburg, tanezumab development team leader, Pfizer Global Product Development. "There is an urgent need for innovation in the treatment of osteoarthritis, as there have been no new classes of medicines available for this debilitating condition in more than a decade. If approved, tanezumab would be a first-in-class treatment for patients suffering from chronic pain due to moderate-to-severe osteoarthritis who have experienced inadequate pain relief with other analgesics."

"Osteoarthritis patients face a significant burden – due to the physical pain they experience, nearly every aspect of their lives can be impacted. This pain can affect their ability to participate in daily activities, which can have significant psychological, social and societal consequences," said Patrik Jonsson, president, Lilly Bio-Medicines. "We look forward to working closely with the FDA to potentially bring tanezumab to patients living with moderate-to-severe osteoarthritis

Buy Monoclonal Antibody Therapeutics Market analysis & forecast 2020-2024 Report along with complete TOC@ https://www.businessindustryreports.com/buy-now/263490/single

Asia Pacific was a prominent market for Monoclonal Antibody Therapeuticss in 2016. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India. These countries have been witnessing rapid increase in its population along with expansion of their overall economies, which has led to increase in disposable income. Increased spending on home interiors is fuelling the Monoclonal Antibody Therapeutics market in Asia Pacific.

There are several manufacturers of Monoclonal Antibody Therapeuticss in Europe and North America. In North America, the demand for Monoclonal Antibody Therapeuticss is primarily driven by the residential sector. Improved standards of living and rising usage of Monoclonal Antibody Therapeuticss for flooring purpose are anticipated to drive the market in North America.

Get Best Discount On This Report @ https://www.businessindustryreports.com/check-discount/263490 

Table of Contents:

Global Monoclonal Antibody Therapeutics Market Report 2020

1 Monoclonal Antibody Therapeutics Definition

2 Global Monoclonal Antibody Therapeutics Market Major Player Share and Market Overview

3 Major Player Monoclonal Antibody Therapeutics Business Introduction

4 Global Monoclonal Antibody Therapeutics Market Segmentation (Region Level)

5 Global Monoclonal Antibody Therapeutics Market Segmentation (Product Type Level)

6 Global Monoclonal Antibody Therapeutics Market Segmentation (Industry Level)

7 Global Monoclonal Antibody Therapeutics Market Segmentation (Channel Level)

8 Monoclonal Antibody Therapeutics Market Forecast 2020-2024

………………. Request free sample to get a complete Table of Content

About us

BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.

Media Contact

Business Industry Reports

Pune – India

sales@businessindustryreports.com

+19376349940

This release was published on openPR.